CAF Accepting Applications for 2025 - 2026 Medical Research Grants & Fellowships
The Cooley’s Anemia Foundation is accepting applications for medical research grants and fellowships in areas related to Thalassemia. The awards are in three categories:
- Clinical Trials in Thalassemia Cell & Gene Therapy Application
- Clinical Research Application
- Research Fellowship Application
Details are as follows:
Clinical Trials in Thalassemia Cell and Gene Therapy Application
The Cooley’s Anemia Foundation invites national and international applicants to apply for grants to facilitate clinical trials in Cell and Gene Therapy to advance a cure for Thalassemia. Both phase I (safety) and phase II (efficacy) trials are eligible for support.
Funding and Candidate Eligibility
Applicants should state the status of their proposed trials, e.g., whether approved by the FDA or equivalent non-US processes or if regulatory review meetings have been scheduled. Studies proposed for this RFA must include a realistic timeline for human trials. The Foundation requests careful documentation of other support and cost allocations. Allowed expenses include:
- Clinical-grade vector production and quality control
- Research subject assessments
- Late-preclinical studies and ex vivo studies on subjects for safety and efficacy assessments
- Patient care costs directly related to the study
- Research assistant or nursing support
Total funding of up to $75,000 per year is available (including 8% indirect costs). Grants may be renewed for a second year with satisfactory progress. Exclusions: lodging and personal costs for research subjects at treatment centers. Investigator support may not exceed 10% of the NIH salary cap.
Letter of Intent
Interested individuals are invited to submit a letter of intent by Monday, December 16, 2024, which includes the name of primary applicant, affiliation, and focus of proposal (not to exceed one paragraph). The completed application is due Monday, February 3, 2025. Both the letter of intent and the application should be emailed in PDF format to grants@thalassemia.org. All applicants will be notified in June 2025 regarding the status of their funding.
Ongoing Clinical Research in Thalassemia Application
The Cooley’s Anemia Foundation invites applicants for grants supporting ongoing clinical research in Thalassemia, addressing issues impacting patients, including cardiac health, fertility, bone health, quality of life, and psychosocial impacts.
Funding: $50,000 annually with a possible one-year renewal. Funds can cover salary or non-salary purposes, with a 10% limit on administrative costs. Appropriate for pilot studies, observational trials, or ancillary support for ongoing studies.
Letter of Intent
Interested individuals are invited to submit a letter of intent by Monday, December 16, 2024, which includes the name of primary applicant, affiliation, and focus of proposal (not to exceed one paragraph). The completed application (including letters of reference, which must be submitted by the authors of the letters) is due Monday, February 3, 2025. Both the letter of intent and the application should be emailed in PDF format to grants@thalassemia.org. All applicants will be notified in June 2025 regarding the status of their funding.
Research Fellowship Grant Application
The Cooley’s Anemia Foundation invites clinical and basic science investigators (postdoctoral or junior faculty) to apply for a fellowship focused on thalassemia or related complications.
Postdoctoral applicants must have adequate mentorship and research facilities. Junior faculty applicants need a research-ready institution and do not require sponsors. Preference goes to those without NIH R-01 funding.
Application Due Date:
Interested individuals are invited to complete and return applications in PDF format via email (grants@thalassemia.org) no later than Monday, February 3, 2025. Letters of reference, which must be sent in separately, must also be received no later than Monday, February 3, 2025. All applicants will be notified in June 2025; regarding the status of their funding.